Problems of tumor growth immunology and antitumor vaccines

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The development of anticancer biotherapeutic methods based on immunopathological features of malignant cells and the search of new approaches is of current importance. The unswering increase of cancer incidence, low overall survival in stage 4 disease, moderate efficacy of contemporary methods in such patients, call forth the social importance of this problem. From the other point of view understanding of immune protection mechanisms, analysis of its failure and development of correction methods are very important.

In this review we discuss the conception of immunologic identification, kinetics of antitumor immune response, mechanisms with which cancer cells avoid immunological surveillance, clinical importance of tumor associated antigens and the scope of treatment with antitumor vaccines.

About the authors

V. M. Moiseyenko

N. N. Petrov Oncology Institute

Author for correspondence.
Email: medaj@eco-vector.com
Russian Federation, St. Petersburg, 197758

I. A. Baldueva

N. N. Petrov Oncology Institute

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg, 197758

References

  1. Балдуева И. А., Моисеенко В. М., Хансон К. П. Система дендритных клеток и их роль в регуляции функциональной активности Т- и В-лимфоцитов // Вопросы онкологии. 1999. Т. 45. № 5. С. 473-483.
  2. Барышников А. Ю., Кадагидзе 3. Г., Махонова Л. А., Тупицын Н. Н. Иммунологический фенотип лейкозной клетки. М.: Медицина, 1989. 240 с.
  3. Ломакин М. С. Иммунобиологический надзор. М.: Медицина, 1990. 256 с.
  4. Моисеенко В. М., Балдуева И. А., Хансон К. П. Вакцинотерапия больных солидными опухолями // Вопросы онкологии. 1999. Т. 45. № 3. С. 327-332.
  5. Петров Р. В., Хаитов Р. М., Манъко В. М., Михайлова А. А. Контроль и регуляция иммунного ответа. Л.: Медицина, 1981. 311 с.
  6. Якубовская Р. И. Современные подходы к биотерапии рака // Рос. биотер. журн. 2002. Т. 1. № 3. С. 5-14.
  7. Aerts-Toegaert C., Heirman C., Tuyaerts S. et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responces // Eur. J. Immunol. 2007. Vol. 37. P. 686-695.
  8. Athie-Morales V., Smits H. H., Cantrell D. A., Hilkens С. M. U. Sustained IL-12 signaling is required for Thl development // J. Immunol. 2004. Vol. 172. P. 61-69.
  9. Ayyoub M., Hesdorffer S., Metther G. et al. Identification of an SSX epitope presented by dendritic cells to circulating autologous CD4+ T cells//J. Immunol. 2004. Vol. 172. P. 7206-7211.
  10. Banchereau J., Briere F., Caux C. et al. Immunobiology of dendritic cells // Ann. Rev. Immunol. 2000. Vol. 18. P. 161-111.
  11. Becker Y. Molecular immunological approaches to biotherapy of human cancer - a review, hypothesis and implications // Anticancer Res. 2006. Vol. 26. P. 1113-1134.
  12. Bitton R. J., Gutmann M. D., Gabri M. R. et al. Cancer vaccines: An update with special focus on ganglioside antigens (Review) // Oncol. Rep. 2002. Vol. 9. P. 267-276.
  13. Boehm T., Zufall F. MHC peptides and the sensory evaluation of genotype // Trends Neurosci. 2006. Vol. 29. P. 100-107.
  14. Boon T. Toward a genetic analysis of tumor rejection antigens // Adv. Cancer Res. 1992. Vol. 58. P. 177-210.
  15. Carlo E. D., Comes A., Orengo A. M. et al. IL-21 induces tumor rejection by specific CTL and IFN-y-dependent CXC chemokines in syngeneic mice // J. Immunol. 2004. Vol. 172. P. 1540-1547.
  16. Chen M. L., Pittet M. J., Gorelik L. et al. Regulatory T cells suppressor tumor-specific CD8 T cell cytotoxicity through TGF-P signals in vivo // Proc. Natl. Acad. Sci. USA. 2005. Vol. 102. P. 419-424.
  17. Chiringhelli F., Zitvogel L. Vaccine strategies against melanoma // Med. Sci. (Paris). 2006. Vol. 22. P. 183-187.
  18. Coulie P. G., Weynants P., Lehmann F. et al. Genes coding for tumor antigens recognized by human cytolytic T lymphocytes // J. Immunother. 1993. Vol. 14. P. 104-109.
  19. Dranoff G. GM-CSF-based cancer vaccines // Immunol. Rev. 2002. Vol. 188. P. 147-154.
  20. Faroudi M., Zaru R., Paulet P. et al. Cutting edge: T lymphocyte activation by repeated immunological synapse formation and intermittent signaling //J. Immunol. 2003. Vol. 171. P. 1128-1132.
  21. Frey A. B. Myeloid suppressor cells regulate the adaptive immune response to cancer // J. Clin. Invest. 2006. Vol. 116. P. 2587-2590.
  22. Gabrilovich D. Mechanisms and functional significance of tumor-induced dendritic-cell defects // Nat. Rev. Immunol. 2004. Vol. 4. P. 941-952.
  23. Gnjatic S., Atanackovic D., Jager E. et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. P. 8862-8867.
  24. Godelaine D., Carrasco J., Brasseur F. et al. A new tumor-specific antigen encoded by MAGE- C2 and presented to cytolytic T lymphocytes by HLA-B44 // Cancer Immunol. Immunother. 2007. Vol. 56. P. 753-759.
  25. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line // Cancer Res. 1943. Vol. 3. P. 326.
  26. Hamilton S. E., Wolkers M. C., Schoenberger S. P., Jamerson S. C. The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells // Nat. Immunol. 2006. Vol. 7. R 439-441.
  27. Helling F., Zhang S., Shang A. et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21 // Cancer Res. 1995. Vol. 55. P. 2783-2788.
  28. Jager E., Jager D., Karbach J. et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4* 0101-0103 and recognized by CD4 (+) T lymphocytes of patients with NY-ESO-1-expressing melanoma // J. Exp. Med. 2000. Vol. 191. P. 625-630.
  29. Jin Y., Fuller L., Esquenazi V. et al. Induction of auto-reactive regulatory T cells by stimulation with immature autologous dendritic cells // Immunol. Invest. 2007. Vol. 36. P. 213-232.
  30. Jones B., Janeway C. A. Cooperative interactions of В lymphocytes with antigen-specific helper T lymphocytes is MHC-restricted // Nature (bond.). 1981. Vol. 292. P. 547.
  31. Koneru M., Schaer D., Monu N. et al. Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function // J. Immunol. 2005. Vol. 174. P. 1830-1840.
  32. Krymskaya L., Lee W.-H., Zhong L., Liu C.-P. Polarized development of memory cell-like IFN-y-producing cells in the absence of TCR ξ-chain // J. Immunol. 2005. Vol. 174. P. 1188-1195.
  33. Lahery D. A., Pardoll D. M., Jaffee E. M. Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology // Mol. Cancer Ther. 2005. Vol. 4. P. 1645-1652.
  34. Lambert P-H., Liu M., Siegrist C-A. Can successful vaccines teach us how to induce efficient protective immune responses? // Nat. Med. 2005. Vol. 11. P. S54-S62.
  35. Liu K., Caldwell S. A., Greeneltch К. M. et al. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape // J. Immunol. 2006. Vol. 176. P. 3374-3382.
  36. Liu K., Idoyaga J., Charalambous A. et al. Innate NKT lymphocytes confer sonfer superior adaptive immunity via tumor-capturing dendritic cells // J. Exp. Med. 2005. Vol. 202. P. 1507-1516.
  37. Lopez-Botet M., Angulo A., Guma M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection // Tissue Antigens. 2004. Vol. 63. P. 195-203.
  38. Luiten R. M., Kueter E. W., Mooi W. et al. Immunogenicity, including vitiligo and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients // J. Clin. Oncol. 2005. Vol. 23. P. 8978-8991.
  39. Lukacs К. V., Pardo О. E., Colston M. J. et al. Heat shock protein in cancer therapy / Cancer Gene Therapy: Springer Netherlands. 2006. Vol. 465. P. 363-368.
  40. Marchand M., Weynants P., Rankin E. et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 // Int. J. Cancer. 1995. Vol. 63. P. 883.
  41. Mocellin S., Lise M., Nitti D. Tumor immunology // Adv. Exp. Med. Biol. 2007. Vol. 593. P. 147-156.
  42. Moiseyenko V. M., Danilov A. O., Baldueva I. A. et al. Phase I/II Trial of Gene Therapy with the Autologous Tumor Cells Modified with the tag7/PGRP-S Gene in Patients with the Disseminated Solid Tumors // Ann. Oncol. 2005. Vol. 16. P. 162-168.
  43. North R. Down-regulation of the antitumor immune response // Adv. Cancer Res. 1985. Vol. 45. P. 1-43.
  44. Palmer D. C., Balasubramaniam S., Hanada K. et al. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction // J. Immunol. 2004. Vol. 173. P. 7209-7216.
  45. Parkhurst M. R., Salgaller M. L., Southwood S. et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gplOO modified at HLA-A*0201-binding residues // J. Immunol. 1995. Vol. 157. P 25-39.
  46. Phan G. Q., Touloukian С. E., Yang J. C. et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens // J. Immunother. 2003. Vol. 26. P. 349-356.
  47. Prehn T. T., Main J. M. Immunity to methyl-cholanthrene-induced sarcomas // J. Natl. Cancer. Inst. 1957. Vol. 18. P.769.
  48. Radoja S., Rao T. D., Hillman D., Frey A. B. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and iq vivo // J. Immunol. 2000. Vol. 164. P. 2619-2628.
  49. Ribas A., Butterfield L. H, Glaspy J. A., Economou J. S. Current development in cancer vaccines and cellular immunotherapy // J. Clin. Oncol. 2003. Vol. 21. P. 2415-2432.
  50. Robertson N. J., Chai J. G., Millrain M. et al. Natural regulation of immunity to minor histocompatibility antigens // J. Immunol. 2007. Vol. 178. P. 3558-3565.
  51. Romero P., Valmori D., Pittet M. J. et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma // Immunol. Rev. 2002. Vol. 188. P. 81-96.
  52. Rosenberg S. A., Dudley M. E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes // Proc. Natl. Acad. Sci. USA. 2004. Vol. 101 (Suppl. 2). P. 14639-14645.
  53. Sahin U., Tureci O., Schmitt H. et al. Human neoplasms elicit multiple specific immune responses in the autologous host stage // Proc. Natl. Acad. Sci. USA. 1995. Vol. 92. P. 11810-118103.
  54. Salcedo R., Stauffer J. K., Lincoln E. et al. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells // J. Immunol. 2004. Vol. 173. P.7170-7182.
  55. Segal N. H., Вlachere N. E., Guevara-Patino J. A. et al. Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics // Cancer Immunol. 2005. Vol. 5. P. 2.
  56. Sosman J., Unger J., Liu P. et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome // J. Clin. Oncol. 2002. Vol. 20. P. 2058-2066.
  57. Steinman R. M., Cohn Z. A. Identification of novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution//J. Exp. Med. 1973. Vol. 137. P. 1142-1162.
  58. Tarabon V. Y., Rowley T. F., Al-Shamkhani A. A critical role for CD70 in CD8 T cell priming by CD40-licensed APCs // J. Immunol. 2004. Vol. 173. P. 6542-6546.
  59. van Mierlo G. J. D., Boonman Z. F. H. M., Dumortier H. M. H. et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication // J. Immunol. 2004. Vol. 173. P. 6753-6759.
  60. Woglom W. Immunity to transplantable tumors // Cancer Res. 1929. Vol. 4. P. 129.
  61. Xia C. Q., Peng R., Annamalai M. et al. Dendritic cells post-maturation are reprogrammed with heightened IFN-gamma and IL-10 // Biochem. Biophys. Res. Commun. 2007. Vol. 352. P. 960-965.
  62. Yasuda T., Kamigaki T, Nakamura T. et al. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells // Oncol. Rep. 2006. Vol. 16. P. 1317-1324.
  63. Yu P., Lee Y., Liu W. et al. Intratumoral depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors // J. Exp. Med. 2005. Vol. 201. P. 779-791.
  64. Zarling A. L., Polefrone J. M., Evans A. M. et al. Identification of class I МНС-associated phosphopeptides as targets for cancer immunotherapy // Proc. Natl. Acad. Sci. USA. 2006. Vol. 103. P. 14889-14894.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2007 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.